Amplia Therapeutics Limited

Amplia Therapeutics Limited (ASX:ATX) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Amplia has two core patent families over its FAK assets. Their ideology is that FAK is an increasingly important target in the field of cancer immunology and that FAK inhibition has the potential to sensitize treatment-resistant cancers to the existing chemotherapeutics. With FAK in mind, Amplia has a particular development focus in pancreatic and ovarian cancer.